Developing drug prototypes: pharmacology replaces safety and tolerability? (original) (raw)

• William Withering. An Account of the Foxglove and its Medical Uses (Oxford Univ. Press, London, 1785).
• Ng, R. Drugs. From discovery to approval 2nd edn (John Wiley & Sons, Hoboken, New Jersey, 2009).
  Google Scholar
• Rang, H. P. Drug Discovery and Development. 1st edn (Churchill Livingstone, Elsevier, Philadelphia, 2007).
  Google Scholar
• Cross, J. et al. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980–1999. Pharmacoepidemiol. Drug Saf. 11, 439–446 (2002).
  Article Google Scholar
• Bhogal, N. & Combes, R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. Altern. Lab. Anim. 34, 225–239 (2006).
  CAS PubMed Google Scholar
• Clark, R. W. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490–497 (2004).
  Article CAS Google Scholar
• Zhao, L., Jin, W., Rader, D., Packard, C. & Feuerstein, G. A translational medicine perspective of the development of torcetrapib: does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and translational medicine in atherosclerosis drug discovery and development. Biochem. Pharmacol. 78, 315–325 (2009).
  Article CAS Google Scholar
• US Food and Drug Administration. Note for guidance on general considerations for clinical trials. Fed. Regist. 62(242), 66113–66119 (1997).
• Lenfle, S. & Loch, C. Lost roots. How project management settled on the phased approach (and compromised its ability to lead change in modern enterprises). Ecole Polytechnique website [online], (2009).
  Google Scholar
• Loch, C., DeMeyer, A. & Pich, M. Managing the unknown. A new approach to managing high uncertainty and risk in projects. (John Wiley & Sons, Hoboken, New Jersey, 2006).
  Book Google Scholar
• Shuchman, M. Commercializing clinical trials-risks and benefits of the CRO boom. N. Engl. J. Med. 357, 1365–1368 (2007).
  Article CAS Google Scholar
• Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092–1102 (2005).
  Article CAS Google Scholar
• Garnier, J. P. Rebuilding the R&D engine in big pharma. Harv. Bus Rev. 86, 68–70, 72–76, 128 (2008).
  PubMed Google Scholar
• Cuatrecasas, P. Drug discovery in jeopardy. J. Clin. Invest. 116, 2837–2842 (2006).
  Article CAS Google Scholar
• Munos, B. Lessons from 60 years of pharmaceutical innovation. Nature Rev. Drug Discov. 8, 959–968 (2009).
  Article CAS Google Scholar
• Lehman Brothers. The fruits of genomics. Drug pipelines face indigestion until the new biology ripens. (Lehman Brothers, New York, 2001).
• US Food and Drug Administration. Challenge and opportunity on the critical path to new medical products. FDA website [online], (2004).
• Loch, C., Mihm, J. & Huchzermeier, A. Concurrent engineering and design oscillations in complex engineering projects. Concurrent Eng. 11, 187–199 (2003).
  Article Google Scholar
• Allen, T., Thusman, M. & Lee, D. Technology transfer as a function of position in the spectrum from research through development to technical services. Acad. Manage. J. 22, 694–708 (1979).
  Google Scholar
• Roussel P. A., Saad, K. N. & Erickson, T. J. Third generation R&D: Managing the Link to Corporate Strategy 1st edn (Harvard Bus School Press, Boston, Massachusetts, USA, 1991).
  Google Scholar
• Sheiner, L. B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275–291 (1997).
  Article CAS Google Scholar
• Danhof, M., Alvan, G., Dahl, S. G., Kuhlmann, J. & Paintaud, G. Mechanism-based pharmacokinetic–pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22, 1432–1437 (2005).
  Article CAS Google Scholar
• FDA Center for Drug Evaluation and Research. Exploratory I.N.D. Studies. FDA website [online], (2006).
• Kenter, M. J. & Cohen, A. F. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368, 1387–1391 (2006).
  Article CAS Google Scholar
• Cohen, A. Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies. Clin. Pharmacokinet. 47, 373–381 (2008).
  Article CAS Google Scholar
• FDA Center for Drug Evaluation and Research. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Guidance for Industry. FDA website [online], (2005).
• Cohen, A. Should we tolerate tolerability as an objective in early drug development? Br. J. Clin. Pharmacol. 64, 249–252 (2007).
  Article CAS Google Scholar
• Schein, P. S. et al. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Ther. 11, 3–40 (1970).
  Article CAS Google Scholar
• Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H. & Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep. 50, 219–244 (1966).
  CAS PubMed Google Scholar
• Zhou, H. et al. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J. Clin. Pharmacol. 39, 911–919 (1999).
  Article CAS Google Scholar
• Appel, S., Kumle, A., Hubert, M. & Duvauchelle, T. First pharmacokinetic–pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. J. Clin. Pharmacol. 37, 229–237 (1997).
  Article CAS Google Scholar
• Chan K. Y. et al. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur. J. Pharmacol. 619, 61–67 (2009).
  Article CAS Google Scholar
• Farzaneh, L., Kasahara, N. & Farzaneh, F. The strange case of TGN1412. Cancer Immunol. Immunother. 56, 129–134 (2007).
  Article CAS Google Scholar
• Legrand, N. et al. Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in “human immune system” Rag2(−/−)γc(−/−) mice. Blood 108, 238–245 (2006).
  Article CAS Google Scholar
• Expert Scientific Group on Phase One clinical Trials. Final Report (The Stationary Office, Norwich, UK, 2006).
• de Visser, S. J. et al. Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients. Clin. Pharmacol. Ther. 72, 419–428 (2002).
  Article CAS Google Scholar
• van der Post, J. P., de Visser, S. J., Schoemaker, R. C., Cohen, A. F. & van Gerven, J. M. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. J. Psychopharmacol. 18, 221–227 (2004).
  Article CAS Google Scholar
• de Visser, S. J. et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br. J. Clin. Pharmacol. 55, 39–50 (2003).
  Article CAS Google Scholar
• Brisbare-Roch, C. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Med. 13, 150–155 (2007).
  Article CAS Google Scholar
• de Visser, S. J. A question based approach to drug development. Thesis, Leiden Univ. (2003).
  Google Scholar
• Aronson, J. K. & Ferner, R. E. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 327, 1222–1225 (2003).
  Article CAS Google Scholar
• Franson, K. L. & Cohen, A. F. How it works. Br. J. Clin. Pharmacol. 68, 315–317 (2009).
  Article CAS Google Scholar
• Brunton, L., Blumenthal, D., Buxton, I. & Parker, K. Goodman and Gilman's Manual of Pharmacology and Therapeutics (McGraw Hill Medical, USA, 2006).
  Google Scholar
• Dollery, C. T. Clinical pharmacology in the molecular era. Clin. Pharmacol. Ther. 83, 220–225 (2008).
  Article CAS Google Scholar
• Aronson, J. An account of the foxglove and its medical uses, 1785–1985. (Oxford Univ. Pres, London 1985). Clin. Pharmacol. Ther. 83, 220–225 (2008).
  Google Scholar
• van Gerven, J. M. et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48–8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br. J. Clin. Pharmacol. 44, 487–493 (1997).
  Article CAS Google Scholar